drugset / Trial / NCT01949662
Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer
Phase 2
Active not recruiting
93 enrolled
M.D. Anderson Cancer Center
National Cancer Institute (NCI) · collab
RandomizedParallel-groupDouble-blindSupportive care
Summary
This randomized phase II trial studies how well haloperidol with or without lorazepam works in reducing confusion, disorientation, and inability to think or remember clearly (delirium) in patients with cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment. Palliative therapy with haloperidol and lorazepam may reduce symptoms of delirium and help patients with advanced cancer live more comfortably. It is not yet known whether lorazepam may be an effective treatment for delirium when given with haloperidol.
Timeline
- Start
- 2014-01
- Primary completion
- 2016-08-26
- Completion
- 2028-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lorazepam | Small molecule | 3 mg | Intravenous |
| Background | Haloperidol Decanoate | Small molecule | 8 mg | Intravenous |